1. Home
  2. PRZO vs INAB Comparison

PRZO vs INAB Comparison

Compare PRZO & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ParaZero Technologies Ltd.

PRZO

ParaZero Technologies Ltd.

HOLD

Current Price

$1.26

Market Cap

25.1M

Sector

N/A

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$2.47

Market Cap

22.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRZO
INAB
Founded
2014
2016
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.1M
22.9M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
PRZO
INAB
Price
$1.26
$2.47
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$108.00
AVG Volume (30 Days)
2.7M
177.8K
Earning Date
08-28-2025
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,007,440.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
80.42
N/A
52 Week Low
$0.53
$1.17
52 Week High
$2.15
$12.53

Technical Indicators

Market Signals
Indicator
PRZO
INAB
Relative Strength Index (RSI) 49.82 57.65
Support Level $1.15 $2.30
Resistance Level $1.35 $2.73
Average True Range (ATR) 0.15 0.25
MACD 0.01 -0.00
Stochastic Oscillator 39.73 50.79

Price Performance

Historical Comparison
PRZO
INAB

About PRZO ParaZero Technologies Ltd.

ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: